ChinaBio® Today Articles

Welcome to the ChinaBio® Today store. As a service to our readers, we offer access to individual articles for only $5.00 (USD) each.  Of course, a subscription is only $20/mo, so you may prefer to subscribe.  If so, click on Subscribe in the menu.

Browse


All Products

Viewing 436 - 450 of 5996 products
Antengene Doses First Patient in Trial of ERK1/2 Inhibitor Combined with BMS’s PD-1
$5.00
Available
HighField Biopharma Starts China Trial of Immune Modulating Liposome for Glioma
$5.00
Available
Kelun-Biotech Raises $174 Million in Hong Kong IPO for ADC Portfolio
$5.00
Available
GeneQuantum Licenses Novel Bioconjugation Technology to InxMed
$5.00
Available
Beijing InnoCare Plans Combined Therapy with Arrivent for NSCLC
$5.00
Available
Connect Reports Progress in Next-gen IL-4Rα Antibody for Atopic Dermatitis
$5.00
Available
GeneQuantum Adds Five ADC Candidates to its Collaboration with Aimed, a Korean Biotech
$5.00
Available
Fosun Pharma Files China NDA for Hyperphosphatemia Therapy in Dialysis Patients
$5.00
Available
Biosyngen to Establish Guangzhou-Singapore Translational Center for Cancer Drugs
$5.00
Available
Sinotau Pharma Completes $152 Million E Round for Radiopharmaceutical Portfolio
$5.00
Available
280Bio, a Yingli Pharma Subsidiary, to Start US Trials of RAS Inhibitor
$5.00
Available
BeiGene Options ADC for Solid Tumor Cancer from Duality Bio in $1.3 Billion Deal
$5.00
Available
WuXi Biologics Plans Spin-off and $500 Million Hong Kong IPO of Conjugates Subsidiary
$5.00
Available
Sirnaomics Provides Capital and RNA Delivery Technology to EDIRNA, an RNA Editing Company
$5.00
Available
Shanghai’s Skyline Approved to Start US Trial of Gene Therapy for Macular Degeneration
$5.00
Available